PeptidePedia The community reference

Contributions of PreregPriya

User contributions·23 logged edits·page 1 of 1

Contributions by PreregPriya, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 5,188 edits includes activity predating the current log.

  1. 05:50, 15 Jun 2026 (diff | hist) Placebo-adjusted effect 4,805 ±0 the trial was open-label; the article implied blinding
  2. 02:00, 10 Jun 2026 (diff | hist) Enteroendocrine L cell 5,083 ±0 m add the postprandial time course with its units
  3. 10:25, 1 Jun 2026 (diff | hist) Talk:Placebo-adjusted effect 537 +134 /* Blinding failure */ new section
  4. 11:43, 21 May 2026 (diff | hist) Drug master file 4,325 ±0 state that a GMP claim is not a fact until assessed
  5. 13:50, 19 May 2026 (diff | hist) Talk:LEADER trial 748 +103 /* Enrichment and generalisation */ reply
  6. 10:20, 24 Apr 2026 (diff | hist) Talk:Weight regain after discontinuation 537 +145 /* Why withdrawal design is needed */ new section
  7. 13:30, 25 Mar 2026 (diff | hist) Talk:TRIUMPH trial programme 611 +187 /* Quoting phase 2 figures */ reply
  8. 13:20, 16 Mar 2026 (diff | hist) Talk:FLOW trial 611 +94 /* Early stopping inflates estimates */ reply
  9. 08:10, 3 Mar 2026 (diff | hist) Talk:Retatrutide 822 +167 /* Phase 2 figures in the lead */ reply
  10. 09:25, 2 Mar 2026 (diff | hist) Talk:Retatrutide 400 +171 /* Phase 2 figures in the lead */ new section
  11. 09:35, 8 Feb 2026 (diff | hist) Talk:STEP trial programme 400 +172 /* Escalation inside the trial duration */ new section
  12. 17:48, 6 Jan 2026 (diff | hist) Patent expiry and biosimilars 4,553 ±0 m add the customs-detention point with its source
  13. 07:30, 24 May 2025 (diff | hist) Karl Fischer titration 7,949 +649 expand §Interpretation on a certificate of analysis
  14. 15:54, 21 May 2025 (diff | hist) Global access disparity 3,314 ±0 expand §Consequences and framing
  15. 00:42, 17 May 2025 (diff | hist) SURMOUNT trial programme 3,589 ±0 name the funder in the sentence, per PP:MOS
  16. 11:03, 7 Apr 2025 (diff | hist) STEP trial programme 4,357 ±0 add the year of publication to each trial in the list
  17. 11:11, 29 Mar 2025 (diff | hist) Bacterial endotoxin test 4,398 ±0 m British spelling per PP:MOS
  18. 09:07, 5 Mar 2025 (diff | hist) Number needed to treat 3,631 ±0 rm a duplicated category
  19. 00:31, 22 Feb 2025 (diff | hist) Peptide aggregation 4,028 +127 m add the reference standard and its traceability
  20. 20:08, 13 Feb 2025 (diff | hist) Dose escalation schedule 3,510 ±0 add the note that a smaller diluent volume raises concentration, not dose
  21. 19:30, 15 Nov 2024 (diff | hist) Solid-phase peptide synthesis 3,861 +484 m expand §Difficult sequences
  22. 08:46, 24 Oct 2024 (diff | hist) LEADER trial 2,357 +170 m add category for the trial programme
  23. 03:23, 15 Oct 2024 (diff | hist) Aspiration risk under anaesthesia 1,230 +1,230 N start article; incidence figures to follow